Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma
An expanded access program of depatuxizumab mafodotin for patients with progressive glioblastoma explores the relationship between tumor EGFR expression and outcomes.
Authors
- Karan Dixit (ORCID: https://orcid.org/0000-0003-0403-6054)
- Ditte Primdahl (ORCID: https://orcid.org/0000-0001-5493-5643)
- Jigisha P. Thakkar (ORCID: https://orcid.org/0000-0003-2635-9444)
- R. Stupp
- Amy B. Heimberger (ORCID: https://orcid.org/0000-0002-9970-8695)
- Lauren Singer (ORCID: https://orcid.org/0000-0002-2432-8305)
- Ruochen Du (ORCID: https://orcid.org/0000-0002-0580-5196)
- Harrshavasan T. S. Congivaram (ORCID: https://orcid.org/0009-0003-5897-0560)
- Margaret Schwartz
- Raymond Lezon
- Kathleen McCortney
- Craig Horbinski
- Rimas V. Lukas
- Priya Kumthekar
Institutions
- Northwestern University (US)
- Loyola University Chicago (US)
- University of Chicago (US)
- Neurological Surgery (US)
Publication Details
- Journal
- JCI Insight
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1172/jci.insight.198475
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00